Summary
For Year 2026-27, Bacil Pharma reports the following shareholding: Total Promoters at 0.08%, Mutual Fund at 0%, Insurance at 0%, Foreign Institutional Investors at 0%, Domestic Institutional Investors at 0%, and Retail at 99.92%. This breakdown provides a quick snapshot of ownership distribution for Bacil Pharma in 2026-27.
Bacil Pharma FAQs
As of 04-2026, the promoter shareholding in Bacil Pharma stands at 0.08% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of Bacil Pharma is 0% and 0% respectively.
The retail shareholding of the Bacil Pharma is 99.92%.
Changes in shareholding patterns of Bacil Pharma can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of Bacil Pharma are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
